APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-05

Price

$134.23

+0.03%

This is the 2026-08-05 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score10.8Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.7xvs 20d avg

Analysis

Apogee Therapeutics (APGE) is trading as a textbook M&A arbitrage play following AbbVie's $10.9 billion ($135.11/share) all-cash acquisition announcement on June 22, 2026. The stock's exceptionally low realized volatility of 1.8% and the 'QUIET_STORM' signal confirm that price action is effectively pinned to the deal terms, while the recent 1.7x volume surge reflects institutional positioning ahead of the upcoming August 11 shareholder vote. Furthermore, the current RISK_ON macro regime and ultra-tight credit spreads (0.78%) provide a highly supportive backdrop, virtually eliminating systemic financing risk and giving arbitrageurs high conviction that the deal will close successfully.

Fired Signals

SURGEALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSMA BOUNCE

Key Takeaways

Actionable Thesis: APGE is a stable M&A arbitrage opportunity, trading at $134.23 to capture the remaining spread up to the $135.11 all-cash buyout price.
Key Risk: Regulatory pushback (FTC/ACCC) or a surprise rejection at the shareholder vote could break the deal, leading to a massive downside repricing.
What to Watch: The August 11 special meeting of stockholders and any subsequent antitrust regulatory clearances.

← Back to 2026-08-05 View Full APGE History →Yahoo Finance &nearr;